Novavax, Inc. Common Stock NVAX
i
Market dataready · fetched 2026-11-10T22:27:41.250Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-13
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T21:51:53.643471626Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-10T22:27:40.782229+00:00
Novavax, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 9.59 | 89.6% | 6.5% | |||
| 30Δ | 9.72 | 82.8% | 5.4% | |||
| 35Δ | 9.86 | 76.1% | 4.3% | |||
| 40Δ | 10.42 | 103.8% | 5.5% | 9.99 | 69.4% | 3.2% |
| 45Δ | 10.30 | 103.7% | 4.8% | 10.05 | 65.9% | 2.8% |
| 50Δ | 10.18 | 103.6% | 4.2% | 10.12 | 62.8% | 2.5% |
| 55Δ | 10.06 | 103.5% | 3.5% | 10.18 | 59.7% | 2.1% |
| 60Δ | 9.92 | 105.3% | 2.9% | 10.24 | 56.7% | 1.8% |
| 65Δ | 9.78 | 108.9% | 2.5% | 10.30 | 53.6% | 1.5% |
| 70Δ | 9.64 | 112.4% | 2.1% | 10.36 | 50.5% | 1.1% |
| 75Δ | 8.84 | 276.0% | 4.3% | |||
| 80Δ | 8.52 | 267.7% | 3.1% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.59
- IV
- 89.6%
- B/E move
- 6.5%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.72
- IV
- 82.8%
- B/E move
- 5.4%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.86
- IV
- 76.1%
- B/E move
- 4.3%
40Δ
- Pseudo strike
- 10.42
- IV
- 103.8%
- B/E move
- 5.5%
- Pseudo strike
- 9.99
- IV
- 69.4%
- B/E move
- 3.2%
45Δ
- Pseudo strike
- 10.30
- IV
- 103.7%
- B/E move
- 4.8%
- Pseudo strike
- 10.05
- IV
- 65.9%
- B/E move
- 2.8%
50Δ
- Pseudo strike
- 10.18
- IV
- 103.6%
- B/E move
- 4.2%
- Pseudo strike
- 10.12
- IV
- 62.8%
- B/E move
- 2.5%
55Δ
- Pseudo strike
- 10.06
- IV
- 103.5%
- B/E move
- 3.5%
- Pseudo strike
- 10.18
- IV
- 59.7%
- B/E move
- 2.1%
60Δ
- Pseudo strike
- 9.92
- IV
- 105.3%
- B/E move
- 2.9%
- Pseudo strike
- 10.24
- IV
- 56.7%
- B/E move
- 1.8%
65Δ
- Pseudo strike
- 9.78
- IV
- 108.9%
- B/E move
- 2.5%
- Pseudo strike
- 10.30
- IV
- 53.6%
- B/E move
- 1.5%
70Δ
- Pseudo strike
- 9.64
- IV
- 112.4%
- B/E move
- 2.1%
- Pseudo strike
- 10.36
- IV
- 50.5%
- B/E move
- 1.1%
75Δ
- Pseudo strike
- 8.84
- IV
- 276.0%
- B/E move
- 4.3%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 8.52
- IV
- 267.7%
- B/E move
- 3.1%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 87.31% | |
| 100.18% | |
| 74.65% | |
| 55.19% | |
| 93.00% | |
| 84.23% | |
| 71.37% | |
| 85.23% | |
| 84.26% | |
| 78.05% | |
| 108.40% | |
| 70.90% | |
| 74.76% | |
| 101.37% | |
| 97.14% | |
| 84.82% | |
| 72.93% | |
| 88.05% | |
| 81.94% | |
| 77.13% | |
| 74.84% | |
| 96.13% | |
| 81.57% | |
| 70.57% | |
| 80.56% | |
| 109.66% | |
| 89.30% | |
| 102.52% | |
| 91.79% | |
| 123.91% | |
| 68.01% | |
| 76.89% | |
| 76.12% | |
| 90.83% | |
| 139.12% | |
| 63.93% | |
| 131.14% | |
| 98.10% | |
| 86.37% | |
| 82.11% | |
| 102.04% | |
| 97.49% | |
| 95.71% | |
| 99.73% | |
| 90.60% | |
| 86.37% | |
| 85.14% | |
| 101.24% | |
| 101.42% | |
| 105.88% | |
| 102.77% | |
| 110.63% | |
| 111.98% | |
| 105.87% | |
| 103.64% | |
| 107.76% |
Biotechnology
NVCT
Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. The company is headquartered in…
More →OABI
OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform. This proprietary technology…
More →OBIO
Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases. The company is headquartered in New…
More →OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern,…
More →OCS
Description unavailable
More →OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its…
More →